Prostate Cancer Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–6 of 6 articles
Pfizer sharpens prostate cancer case with Talzenna win — oncology
New Hormone Regimen Shows Promise for Prostate Cancer Surgery Patients: Study Insights
ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology
New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
Candel's Prostate Cancer Drug: Long-Term Data Insights Ahead of FDA Filing